Soros Fund Management - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 25 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Soros Fund Management ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$20,801,000
+6.1%
32,298,0000.0%0.39%
+5.4%
Q4 2020$19,611,000
+44.8%
32,298,000
+65.2%
0.37%
+11.4%
Q3 2020$13,548,00019,552,0000.33%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 55,943,000$39,071,0002.11%
PenderFund Capital Management Ltd. 5,000,000$4,719,0001.31%
Opti Capital Management, LP 13,246,000$9,340,0001.14%
Context Partners Fund, L.P. 7,485,000$5,145,0001.12%
Context Capital Management, LLC 7,485,000$5,145,0001.12%
Soros Fund Management 19,552,000$13,548,0000.33%
ADVENT CAPITAL MANAGEMENT /DE/ 18,604,000$12,963,0000.29%
Senvest Management, LLC 5,000,000$3,465,0000.20%
CSS LLC/IL 2,825,000$1,957,0000.09%
GABELLI & Co INVESTMENT ADVISERS, INC. 350,000$243,0000.04%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders